NCT05451407View on ClinicalTrials.gov

Efficacy and Safety of TQB2618 Injection Combined With Toripalimab Injection in Patients With Advanced Melanoma

PHASE1UnknownINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

August 9, 2022

Primary Completion Date

October 31, 2023

Study Completion Date

December 31, 2023

Conditions
Melanoma
Interventions
DRUG

TQB2618 injection

Humanized IgG4 mab targeting TIM-3

DRUG

Toripalimab injection

Monoclonal antibody against Programmed death factor receptor 1

Trial Locations (1)

100142

RECRUITING

Peking University Cancer Hospital, Beijing

Sponsors
All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY